Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Interest with Marathon

<< Previous

Bullboard Posts

Next >>

Comment by palinc2000on Sep 20, 2024 9:34am

112 Views

Post# 36232796

RE:Interest with Marathon

The Secured Overnight Financing Rate SOFR) went down by 51 points on Sept 19
As I recall the interest rate paid by Thtx is based on SOFR plus 9.50
So there is a small saving but the SOFR rate has gone up by more than 4% since the oriiginal loan agreement

juniper88 wrote: This is a question for posters like Palinc who know about this financing a lot more than I do.

The 50 basis point cut by the Feb, does it have an impact on the interest rate Thera pays Marathon? I thought it was a variable rate. If yes, how much would thera be saving per quarter?

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages